Cargando…

Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice

BACKGROUND: In children with phenylketonuria (PKU), transitioning protein substitutes at the appropriate developmental age is essential to help with their long-term acceptance and ease of administration. We assessed the parental experiences in transitioning from a second stage to third stage liquid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Ozlem, Pinto, Alex, Daly, Anne, Ashmore, Catherine, Evans, Sharon, Yabanci Ayhan, Nurcan, MacDonald, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615388/
https://www.ncbi.nlm.nih.gov/pubmed/36303225
http://dx.doi.org/10.1186/s13023-022-02555-8
_version_ 1784820411198865408
author Yilmaz, Ozlem
Pinto, Alex
Daly, Anne
Ashmore, Catherine
Evans, Sharon
Yabanci Ayhan, Nurcan
MacDonald, Anita
author_facet Yilmaz, Ozlem
Pinto, Alex
Daly, Anne
Ashmore, Catherine
Evans, Sharon
Yabanci Ayhan, Nurcan
MacDonald, Anita
author_sort Yilmaz, Ozlem
collection PubMed
description BACKGROUND: In children with phenylketonuria (PKU), transitioning protein substitutes at the appropriate developmental age is essential to help with their long-term acceptance and ease of administration. We assessed the parental experiences in transitioning from a second stage to third stage liquid or powdered protein substitute in patients with PKU. RESULTS: Sixteen interviews (23 open-ended questions) were carried out with parents/caregivers of children with PKU (8 females, 50%) with a median age of 8 years (range 5–11 years), continuously treated with diet, and on a third stage protein substitute. Parents/caregivers identified common facilitators and barriers during the third stage protein substitute transition process. The main facilitators were: child and parent motivation, parent knowledge of the transition process, a role model with PKU, low volume and easy preparation of the third stage protein substitute (liquid/powder), anticipation of increasing child independence, lower parent workload, attractive packaging, better taste and smell, school and teacher support, dietetic plans and guidance, PKU social events, child educational materials and written resources. The main barriers were child aversion to new protein substitutes, poor child behaviour, child aged > 5 years, parental fear of change, the necessity for  parental time and persistence, loss of parental control, high product volume, different taste, smell, and texture of new protein substitutes, and peer bullying. CONCLUSION: A stepwise, supportive approach is necessary when transitioning from second to third stage protein substitutes in PKU. Future studies are needed to develop guidance to assist parents/caregivers, health professionals, and teachers during the transition process.
format Online
Article
Text
id pubmed-9615388
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96153882022-10-29 Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice Yilmaz, Ozlem Pinto, Alex Daly, Anne Ashmore, Catherine Evans, Sharon Yabanci Ayhan, Nurcan MacDonald, Anita Orphanet J Rare Dis Research BACKGROUND: In children with phenylketonuria (PKU), transitioning protein substitutes at the appropriate developmental age is essential to help with their long-term acceptance and ease of administration. We assessed the parental experiences in transitioning from a second stage to third stage liquid or powdered protein substitute in patients with PKU. RESULTS: Sixteen interviews (23 open-ended questions) were carried out with parents/caregivers of children with PKU (8 females, 50%) with a median age of 8 years (range 5–11 years), continuously treated with diet, and on a third stage protein substitute. Parents/caregivers identified common facilitators and barriers during the third stage protein substitute transition process. The main facilitators were: child and parent motivation, parent knowledge of the transition process, a role model with PKU, low volume and easy preparation of the third stage protein substitute (liquid/powder), anticipation of increasing child independence, lower parent workload, attractive packaging, better taste and smell, school and teacher support, dietetic plans and guidance, PKU social events, child educational materials and written resources. The main barriers were child aversion to new protein substitutes, poor child behaviour, child aged > 5 years, parental fear of change, the necessity for  parental time and persistence, loss of parental control, high product volume, different taste, smell, and texture of new protein substitutes, and peer bullying. CONCLUSION: A stepwise, supportive approach is necessary when transitioning from second to third stage protein substitutes in PKU. Future studies are needed to develop guidance to assist parents/caregivers, health professionals, and teachers during the transition process. BioMed Central 2022-10-27 /pmc/articles/PMC9615388/ /pubmed/36303225 http://dx.doi.org/10.1186/s13023-022-02555-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yilmaz, Ozlem
Pinto, Alex
Daly, Anne
Ashmore, Catherine
Evans, Sharon
Yabanci Ayhan, Nurcan
MacDonald, Anita
Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title_full Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title_fullStr Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title_full_unstemmed Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title_short Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
title_sort transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615388/
https://www.ncbi.nlm.nih.gov/pubmed/36303225
http://dx.doi.org/10.1186/s13023-022-02555-8
work_keys_str_mv AT yilmazozlem transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT pintoalex transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT dalyanne transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT ashmorecatherine transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT evanssharon transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT yabanciayhannurcan transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice
AT macdonaldanita transitioningofproteinsubstitutesinpatientswithphenylketonuriaevaluationofcurrentpractice